Microrna-130b regulates scleroderma fi brosis by targeting peroxisome proliferator-activated receptor g

Modern Rheumatology

Volumn 25, Issue 4, 2015, Pages 595-602

  Luo, Hui ^a   Zhu, Honglin ^a   Zhou, Bin ^a   Xiao, Xianzhong ^b   Zuo, Xiaoxia ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

MiR 130b; PPAR ; Scleroderma; TGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; COLLAGEN TYPE 1 ALPHA 2; FIBRONECTIN; HYDROXYPROLINE; LIPOFECTAMINE; MICRORNA; MICRORNA 130B; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; MIRN130 MICRORNA, MOUSE; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; FEMALE; FIBROBLAST; GENE DELETION; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSFECTION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; WESTERN BLOTTING; ANIMAL; BIOPSY; BIOSYNTHESIS; CELL CULTURE; DBA MOUSE; DISEASE MODEL; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BIOPSY; BLOTTING, WESTERN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED DBA; MICRORNAS; PPAR GAMMA; REAL-TIME POLYMERASE CHAIN REACTION; RNA; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 84934944846     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.1001311     Document Type: Article

References (34)

1. Bhattacharyya S, Wei J, Varga J. Understanding fi brosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2012;8(1):42–54.
2. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol. 2009;5(4):200–6.
3. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350–8.
4. Wei J, Bhattacharyya S, Varga J. Peroxisome proliferator-activated receptor gamma: innate protection from excessive fi brogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol. 2010;22(6):671–6.
5. Wei J, Bhattacharyya S, Jain M, Varga J. Regulation of matrix remodeling by peroxisome proliferator-activated receptor-gamma: a novel link between metabolism and fi brogenesis. Open Rheumatol J. 2012;6:103–15.
6. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J. Disruption of transforming growth factor beta signaling and profi brotic responses in normal skin fi broblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum. 2004;50(4):1305–18.
7. Deng YL, Xiong XZ, Cheng NS. Organ fi brosis inhibited by blocking transforming growth factor-beta signaling via peroxisome proliferator-activated receptor gamma agonists. Hepatobiliary Pancreat Dis Int. 2012;11(5):467–78.
8. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 2008;9(3):219–30.
9. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007;23:175–205.
10. Jiang X, Tsitsiou E, Herrick SE, Lindsay MA. MicroRNAs and the regulation of fibrosis. FEBS J. 2010;277(9):2015–21.
11. Li H, Yang R, Fan X, Gu T, Zhao Z, Chang D, Wang W. MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol Int. 2012;32(2):307–13.
12. Zhu H, Li Y, Qu S, Luo H, Zhou Y, Wang Y, et al. MicroRNA expression abnormalities in limited cutaneous scleroderma and diff use cutaneous scleroderma. J Clin Immunol. 2012;32(3):514–22.
13. Zhu H, Luo H, Zuo X. MicroRNAs: their involvement in fi brosis pathogenesis and use as diagnostic biomarkers in scleroderma. Exp Mol Med. 2013;45:e41.
14. Preliminary criteria for the classifi cation of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581–90.
15. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classifi cation, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–5.
16. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8.
17. Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, et al. Treatment with imatinib prevents fi brosis in diff erent preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009;60(1):219–24.
18. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007;56(1):311–22.
19. Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ. Rosiglitazone alleviates the persistent fi brotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology (Oxford). 2010;49(2):259–63.
20. Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, Leask A. Loss of peroxisome proliferator-activated receptor gamma in mouse fi broblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum. 2009;60(9):2822–9.
21. Wang YC, Li Y, Wang XY, Zhang D, Zhang H, Wu Q, et al. Circulating miR-130b mediates metabolic crosstalk between fat and muscle in overweight/obesity. Diabetologia. 2013;56(10):2275–85.
22. Lee EK, Lee MJ, Abdelmohsen K, Kim W, Kim MM, Srikantan S, Martindale JL, et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol. 2011;31(4):626–38.
23. Pan S, Zheng Y, Zhao R, Yang X. MicroRNA-130b and microRNA-374b mediate the eff ect of maternal dietary protein on off spring lipid metabolism in Meishan pigs. Br J Nutr. 2013;109(10):1731–8.
24. Peyrou M, Ramadori P, Bourgoin L, Foti M. PPARs in liver diseases and cancer: epigenetic regulation by MicroRNAs. PPAR Res. 2012;2012:757803.
25. Maurer B, Stanczyk J, Jungel A, Akhmetshina A, Trenkmann M, Brock M, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 2010;62(6):1733–43.
26. Zhu H, Luo H, Li Y, Zhou Y, Jiang Y, Chai J, et al. MicroRNA-21 in scleroderma fi brosis and its function in TGF-beta-regulated fi brosis-related genes expression. J Clin Immunol. 2013;33(6):1100–9.
27. Lefterova MI, Haakonsson AK, Lazar MA, Mandrup S. PPARgamma and the global map of adipogenesis and beyond. Trends Endocrinol Metab. 2014.
28. Sime PJ. The antifi brogenic potential of PPARgamma ligands in pulmonary fibrosis. J Investig Med. 2008;56(2):534–8.
29. Dekkers JF, van der Ent CK, Kalkhoven E, Beekman JM. PPARgamma as a therapeutic target in cystic fibrosis. Trends Mol Med. 2012;18(5):283–91.
30. Lee CH, Kim HD, Shin SM, Kim SG. A novel mechanism of PPARgamma regulation of TGFbeta1: implication in cancer biology. PPAR Res. 2008;2008:762398.
31. Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, et al. Toll-like receptor 4 signaling augments transforming growth factor-beta responses: a novel mechanism for maintaining and amplifying fi brosis in scleroderma. Am J Pathol. 2013;182(1):192–205.
32. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et al. A SUMOylation-dependent pathway mediates transrepression of infl ammatory response genes by PPAR-gamma. Nature. 2005;437(7059):759–763.
33. Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, et al. Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fi brotic responses in mesenchymal cells. Arthritis Rheum. 2012;64(8):2734–45.
34. Zhang S, Chen L, Jung EJ, Calin GA. Targeting microRNAs with small molecules: from dream to reality. Clin Pharmacol Ther. 2010;87(6):754–8.